Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1184 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Ciltacabtagene autoleucel for relapsed and refractory multiple myeloma	Ciltacabtagene Autoleucel (JNJ-68284528; LCAR-B38M CAR-T cell therapy; LCAR-B38M; JNJ 4528)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas , Haematology	2021	View \| Download
Ciclosporin ophthalmic solution for treating moderate-to-severe keratoconjunctivitis sicca (dry eye disease)	Ciclosporin ophthalmic solution	Keratoconjunctivitis sicca (dry eye disease)	Ophthalmology	2023	View \| Download
Cethrin for traumatic spinal cord injury	Cethrin (BA 210; VX-210)	Spinal cord injury	Musculoskeletal System	2017	View \| Download
Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults	Certolizumab (CDP-870; Cimzia; certolizumab pegol)	Plaque psoriasis	Dermatology	2017	View \| Download
CER-001 for Familial Primary Hypoalphalipoproteinemia	CER-001	Familial primary hypoalphalipoproteinemia	Endocrine Nutritional and Metabolic Disorders , Genetic Disorders	2018	View \| Download
Cenobamate for Partial Focal Epilepsy – Adjunctive Therapy	Cenobamate (YKP3089)	Epilepsy	Neurology	2018	View \| Download
Cenobamate as an adjunctive therapy for primary generalised tonic-clonic seizures	Cenobamate (YKP3089)	Primary generalised tonic-clonic seizures	Neurology	2022	View \| Download
Cenicriviroc for non-alcoholic steatohepatitis (NASH)	Cenicriviroc (TAK-652; Cenicriviroc Mesylate)	Non-alcoholic steatohepatitis (NASH)	Hepatology	2017	View \| Download
Cemiplimab in combination with chemotherapy for advanced or metastatic non-small cell lung cancer – first-line	Cemiplimab (Libtayo; REGN2810) , Ipilimumab (Yervoy; BMS 734016; MDX 101)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Cemiplimab for recurrent, persistent or metastatic cervical cancer – second line	Cemiplimab (Libtayo; REGN2810)	Cervical cancer	Female Reproductive Cancer	2020	View \| Download